国家科技部中国科技论文统计源期刊   中国科技核心期刊   WHO西太平洋地区医学索引(WPRIM)收录期刊   湖北优秀期刊
《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>
武汉地区24家医院2008~2010年口服抗糖尿病药使用调查
Analysis of Anti diabetes Drugs in Wuhan Area During the Period of 2008~2010
投稿时间:2011-10-14  
DOI:
中文关键词:  口服抗糖尿病药  限定日剂量  用药频度  日均费用  用药分析
英文关键词:Oral antidiabetic drugs  DDD  DDDs  DDC  Analysis of drug use
基金项目:
作者单位
刘喆隆 华中科技大学同济医学院附属同济医院内分泌科(武汉 430030) 
张程亮 华中科技大学同济医学院附属同济医院药学部 
杜晓军 华中科技大学同济医学院附属同济医院信息中心 
余学锋 华中科技大学同济医学院附属同济医院内分泌科 
刘东 华中科技大学同济医学院附属同济医院药学部 
摘要点击次数: 1289
全文下载次数: 1549
中文摘要:
      摘 要 目的:了解武汉地区2008~2010年口服抗糖尿病药(OADs)使用情况及变化趋势。方法:采用用药金额排序法和限定日剂量法对武汉地区24家医院2008~2010年口服抗糖尿病药使用情况进行统计分析。结果:2008~2010年武汉地区口服抗糖尿病药总用药金额和用药频度逐年上升。销售金额排序前3位的是阿卡波糖、瑞格列奈和二甲双胍,其3年销售金额之和所占比例达61.80%;而用药频度(DDDs)排序前4位的是格列齐特、阿卡波糖、格列美脲和二甲双胍,其3年DDDs之和所占比例达63.79%。格列美脲、格列齐特以及二甲双胍的日均费用(DDC)较低,2010年分别为2.08、2.35和3.42元/d。结论:武汉地区医院口服抗糖尿病药用药结构较为合理、稳定。阿卡波糖和二甲双胍最为临床认可,而格列齐特等磺脲类药物因其较好的性价比仍占重要地位。
英文摘要:
      ABSTRACT Objective: To investigate the status of consumptions and developmental tendency of oral antidiabetic drugs(OADs) in Wuhan area from 2008 to 2010.Method:With the analytical method of the Defined Daily Dose (DDD) recommended by WHO, the relative data of OADs used in 24 hospitals of Wuhan area during the period of 2008 2010 were statistically analyzed.Result:The consumption sum and frequency of drug use of OADs increased year by year. Top 3 OADs in the list of consumption sum were acarbose, repaglinide and metformin as the sum of consumption in the 3 years occupid 61.8% The most frequently used drugs were gliclazide, acarbose, glimepiride and metformin as the sum of the defined daily drugs system(DDDs) occupied 63.79%. Among the drugs listed above, gliclazide,glimepiride and metformin had the lowest daily drug cost (DDC) in 2010 with the costs of 2.08,2.35 and 3.42 yuan per day respectively.Conclusion:The application of OADs in Wuhan was rational and stable. Acarbose and metformin were the most popular drugs in the clinic. The sulphanylureas drugs such as gliclazide still took the important place in the therapy of diabetes because of their good performance of efficacy and cost.
查看全文  查看/发表评论  下载PDF阅读器
关闭